Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Arcutis Biotherapeutics stock on May 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
- Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
- Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.
- Sold $15,001 – $50,000 in shares of Workday (NASDAQ:WDAY) on 5/29/2026.
Arcutis Biotherapeutics Stock Up 2.0%
ARQT traded up $0.46 on Wednesday, hitting $23.25. 1,411,324 shares of the company were exchanged, compared to its average volume of 1,506,896. Arcutis Biotherapeutics, Inc. has a twelve month low of $12.72 and a twelve month high of $31.77. The company has a market cap of $2.91 billion, a price-to-earnings ratio of -774.74 and a beta of 1.51. The company has a current ratio of 2.68, a quick ratio of 2.46 and a debt-to-equity ratio of 0.54. The firm has a 50-day moving average price of $22.48 and a two-hundred day moving average price of $25.37.
Insider Transactions at Arcutis Biotherapeutics
In other news, insider Masaru Matsuda sold 8,256 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $23.31, for a total value of $192,447.36. Following the completion of the sale, the insider directly owned 126,689 shares of the company’s stock, valued at approximately $2,953,120.59. The trade was a 6.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Todd Watanabe sold 3,172 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $74,890.92. Following the completion of the sale, the insider directly owned 720,755 shares of the company’s stock, valued at $17,017,025.55. The trade was a 0.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 31,254 shares of company stock valued at $732,019 over the last quarter. Company insiders own 9.40% of the company’s stock.
Analyst Upgrades and Downgrades
ARQT has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Friday, March 27th. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday, May 7th. Guggenheim boosted their target price on Arcutis Biotherapeutics from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. HC Wainwright boosted their target price on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen cut Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.00.
Read Our Latest Report on ARQT
Institutional Trading of Arcutis Biotherapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. Focus Partners Wealth lifted its holdings in shares of Arcutis Biotherapeutics by 0.8% in the 3rd quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock valued at $1,237,000 after purchasing an additional 490 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Arcutis Biotherapeutics by 1.8% in the 3rd quarter. Arizona State Retirement System now owns 31,685 shares of the company’s stock valued at $597,000 after purchasing an additional 568 shares during the last quarter. Schroder Investment Management Group lifted its holdings in shares of Arcutis Biotherapeutics by 1.1% in the 4th quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock valued at $1,604,000 after purchasing an additional 594 shares during the last quarter. AlphaQuest LLC lifted its holdings in shares of Arcutis Biotherapeutics by 5.7% in the 3rd quarter. AlphaQuest LLC now owns 12,603 shares of the company’s stock valued at $238,000 after purchasing an additional 682 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Arcutis Biotherapeutics by 124.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after purchasing an additional 698 shares during the last quarter.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.
In August 2022, Arcutis received U.S.
Featured Articles
- Five stocks we like better than Arcutis Biotherapeutics
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
